NASDAQ:MAXY - Maxygen Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Maxygen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileEarningsFinancialsHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Maxygen, Inc. (Maxygen) is a biotechnology company focused on the development of its MAXY-G34 product candidate. MAXY-G34 is a pegylated, granulocyte colony stimulating factor (G-CSF), for the treatment of chemotherapy-induced neutropenia and acute radiation syndrome (ARS). On May 16, 2011, Astellas Pharma Inc. (Astellas) acquired the Company's interests in Perseid Therapeutics LLC, the Company's former subsidiary, which included all of the Company's research and development operations. As a result of the transaction, the Company has reclassified the operating results of Perseid, as well as any related business activities, to discontinued operations. The Company's wholly owned subsidiaries include Maxygen Holdings (U.S.), Inc., Maxygen ApS and Maxygen Holdings, Inc., and its majority owned subsidiary, Maxygen Holdings LLC. Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryBiotechnology SectorN/A Current SymbolNASDAQ:MAXY Previous Symbol CUSIP57777610 CIK1068796 Webhttp://www.maxygen.com/ Phone+1-650-2412292Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableNot Optionable Receive MAXY News and Ratings via Email Sign-up to receive the latest news and ratings for MAXY and its competitors with MarketBeat's FREE daily newsletter. Maxygen (NASDAQ:MAXY) Frequently Asked Questions What is Maxygen's stock symbol? Maxygen trades on the NASDAQ under the ticker symbol "MAXY." Has Maxygen been receiving favorable news coverage? Media stories about MAXY stock have been trending somewhat negative recently, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Maxygen earned a coverage optimism score of -1.8 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Maxygen. Who are some of Maxygen's key competitors? Some companies that are related to Maxygen include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). What is Maxygen's official website? The official website for Maxygen is http://www.maxygen.com/. How can I contact Maxygen? Maxygen's mailing address is 725 San Aleso Ave Ste 2, SUNNYVALE, CA 94085-1400, United States. The biotechnology company can be reached via phone at +1-650-2412292. MarketBeat Community Rating for Maxygen (NASDAQ MAXY)Community Ranking: 1.7 out of 5 ()Outperform Votes: 27 (Vote Outperform)Underperform Votes: 52 (Vote Underperform)Total Votes: 79MarketBeat's community ratings are surveys of what our community members think about Maxygen and other stocks. Vote "Outperform" if you believe MAXY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MAXY will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/22/2020 by MarketBeat.com StaffFeatured Article: Certificate of Deposit (CD) For Risk Adverse Investors?